Skip to content
Sharism- Lifestyle
Author:
Electra Therapeutics, Inc.
Electra Therapeutics Reports Third Quarter 2026 Financial Results and Recent Portfolio Highlights
November 12, 2026
Electra Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference in London
November 4, 2026
Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering
September 17, 2026
Electra Therapeutics Announces Initiation of a Phase 1 Trial of ELA822, a Novel SIRPγ-Specific Antibody Designed to Treat T Cell-Mediated Immune and Inflammatory Diseases
September 10, 2026
Electra Therapeutics Appoints Chris Clark, CFA, to Chief Financial Officer
September 9, 2026